Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.41 |
| ▸ | F10 | P00742 | 9/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072175 | 0.99 | SCN9A (0.42) | SCN9AF10PRSS1SCN10AF2 | |
| SCHEMBL7068399 | 0.90 | F10 (0.40) | SCN9AF10PRSS1F2PRSS2 | |
| SCHEMBL7094636 | 0.89 | F10 (0.45) | F10PRSS1F2PLG | |
| SCHEMBL7068684 | 0.87 | PRSS1 (0.43) | SCN9AF10PRSS1SCN10AF2 | |
| SCHEMBL7069895 | 0.87 | F10 (0.48) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7068340 | 0.86 | F10 (0.43) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7072511 | 0.86 | F2 (0.44) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7069979 | 0.86 | F10 (0.44) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7070006 | 0.85 | F10 (0.40) | SCN9AF10PRSS1F2PRSS2 | |
| SCHEMBL7068667 | 0.85 | SCN9A (0.47) | SCN9AF10PRSS1F2PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187037-A1 | Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia | MERCK-PATENT GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187037-A1 | Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia | F12, F11, PLAT | SCN9A 3149/4885F10 17/4885PRSS1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.